


The Schroder Institutional UK Equity Fund's investment objective is to achieve capital growth through investment in UK equities, although considerable attention will be paid to maintaining a steady growth in income distributions.
| Name | % Net Assets | 
|---|---|
| Royal Dutch Shell | 6.0% | 
| GlaxoSmithKline | 5.7% | 
| ANGLO AMERICAN | 5.2% | 
| BG GROUP | 5.0% | 
| GLAXOSMITHKLINE | 5.0% | 
| RIO TINTO | 4.6% | 
| ASTRAZENECA PLC | 4.3% | 
| UNILEVER | 4.3% | 
| HSBC HLDGS | 4.1% | 
| BP | 3.6% | 
| Key | % Net Assets | 
|---|---|
| 6.0% | |
| 5.7% | |
| 5.2% | |
| 5.0% | |
| 78.1% | 
| Date | 20-Aug-2025 | 
|---|---|
| NAV | 264.50p | 
| Currency | GBP | 
| Change | 0.30p | 
| % | 0.11% | 
| YTD change | 28.80p | 
| YTD % | 12.22% | 
| Fund Inception | 06/05/1997 | 
|---|---|
| Fund Manager | Jeremy Smith | 
| TER | - | 
| Minimum Investment | |
|---|---|
| Initial | £1000000 | 
| Additional | n/a | 
| Savings | n/a | 
| Charges | |
|---|---|
| Initial | n/a | 
| Annual Mang't | 0.50% | 
| Exit | n/a | 
| Name | % | 
|---|---|
| Standard deviation | 0.01 | 
| Sharpe ratio | 0.13 | 
You are here: research